Your session is about to expire
← Back to Search
Unknown
16mg,KB for Sepsis
Phase 2
Recruiting
Research Sponsored by Tianjin Chasesun Pharmaceutical Co., LTD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 2, 4 , 8 after the first dose (within 24 hours after the last dose on day 7)
Summary
Phase II study of Kukoamine B Mesilate in Sepsis Patients
Eligible Conditions
- Sepsis
- Staphylococcal Sepsis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 8 after the first dose (within 24 hours after the last dose on day 7)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 8 after the first dose (within 24 hours after the last dose on day 7)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Clinical Outcome Composite Endpoint
Delta SOFA (ΔSOFA)
Duration of ICU stay and absence
+5 moreOther study objectives
Area under the curve at steady state (AUCss)
Correlation between the exposure of Kukoamine B Mesilate and hepatic-related treatment-related adverse events
Correlation between the exposure of Kukoamine B Mesilate and its efficacy
+2 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 16mg,KBExperimental Treatment1 Intervention
Group A:16mg,Q8h±3min,Day1-Day7
Group II: PlacebosPlacebo Group1 Intervention
Group B:Placebos,Q8h±3min,Day1-Day7
Find a Location
Who is running the clinical trial?
Tianjin Chasesun Pharmaceutical Co., LTDLead Sponsor
4 Previous Clinical Trials
216 Total Patients Enrolled
1 Trials studying Sepsis
44 Patients Enrolled for Sepsis
Southwest Hospital, ChinaOTHER
140 Previous Clinical Trials
143,571 Total Patients Enrolled
2 Trials studying Sepsis
104 Patients Enrolled for Sepsis
Share this study with friends
Copy Link
Messenger